Fulvestrant en la práctica clínica: análisis de efectividad en pacientes uruguayas con cáncer de mama HR+/HER2.

Introduction: Fulvestrant demonstrated benefits in overall survival and progression-free survival in patients with advanced breast cancer, who are hormone receptor-positive and human epidermal growth factor receptor 2 negative. The characteristics, evolution, and survival of patients with hormone receptor-positive, HER2-negative breast cancer treated with fulvestrant were evaluated according to the national treatment coverage protocols of the National Resources Fund, with the aim of understanding the efficacy of fulvestrant in patients treated in usual clinical practice and comparing our results with those from pivotal studies.

Methods: A database from the National Resources Fund covering the period from 2009 to 2022 was used.

[Returning to work after diagnosis and treatment of breast cancer].

Background: Returning to work and performing housework tasks (HWT) is the final step in overcoming breast cancer (BC).

Objective: To assess whether clinical characteristics and type of treatment impact employment status and performance of HWT.

Material And Methods: A total of 119 patients diagnosed with early BC were enrolled.